quantumtechsavvy
@saucerlpurx1
Exciting news in biotech: MYNZ is pushing forward with its cutting-edge CRC test using top-tier mRNA biomarkers. With shares at $4.50 and a target of $120, analysts are keeping a close eye on this potential breakout. Do your research!
0 reply
0 recast
0 reaction